- °ßÀû ¹× ÁÖ¹®
- ½ÇÇèÁ¤º¸
- Á¦Ç°/½ÇÇè Q&A
- Ŭ·¹ÀÓ
|
|
|
|
iPS¼¼Æ÷¿¡¼ À¯·¡µÈ human Cardiomyocytes´Â cariotoxicity Å×½ºÆ®, ¾à¹°°Ë»ç, ¾à¹° À¯È¿¼º È®ÀÎ ¹× ½ÅÁø´ë»ç ¿¬±¸, electrophysiology¿¡ »ç¿ëµË´Ï´Ù. ÇØµ¿µÇ¸é in vitro¿¡¼ ÀÚ¹ßÀûÀ¸·Î ¹Úµ¿Çϱ⠽ÃÀÛÇϸç, troponinÀ» Æ÷ÇÔÇÑ ½ÉÀå Æ¯ÀÌ ¸¶Ä¿¸¦ ¹ßÇöÇÕ´Ï´Ù. |
![]() |
||
AXOL |
Cat. No. | Product Name | Quantity |
ax2502 | Human iPSC-Derived Ventricular Cardiomyocytes (Female) | 1 million cells |
ax2505 | Human iPSC-Derived Ventricular Cardiomyocytes (Male) | 1 million cells |
ax2520 | Human iPSC-Derived Ventricular Cardiomyocytes (Male) | 1 million cells |
ax2500 | Human iPSC-Derived Ventricular Cardiomyocyte Kit (Male) | 1 kit (1 million cells) |
ax2515 | Human iPSC-Derived Atrial Cardiomyocytes (Male) | 1 million cells |
ax2530-500 | Cardiomyocyte Maintenance Medium | 500 mL |
ax0044 | Unlock | 25 mL |
ax0049 | Fibronectin Coating Solution | 1 mL |
Axol Human iPSC-Derived Ventricular Cardiomyocytes were cultured in Cardiomyocyte Maintenance Medium prior
to being fixed and stained for the markers Sarcomeric Alpha Actinin and Cardiac Troponin. The cells were
counterstained using DAPI to allow visualization of nuclei. Expression of Troponin T, atrial natriuretic peptide (ANP) and atrial myosin light chain 2 (MLC2a) was confirmed in
Axol iPSC-Derived Atrial Cardiomyocytes using immunocytochemistry. Troponin T staining (red) confirmed the
presence of cardiac myocytes which are responsible for sarcomere contraction. ANP is specifically secreted by
atrial myocytes upon atrial stretching and MLC2a facilitates cardiac contractility wo. DAPI counterstain.
Characteristics of spontaneous and evoked action potentials recorded from Axol’s Human iPSC-derived Ventricular
Cardiomyocytes. Spontaneous (A) and evoked (1 Hz; B) action potentials recorded by whole-cell patch clamp.
(C) Average action potential parameters for spontaneous and evoked action potentials in control conditions.
Axol’s Human iPSC-derived Ventricular Cardiomyocytes express the core cardiac ion channels INa, ICa,L and IKr.
(A) Representative traces of evoked action potentials recorded under control conditions (grey) and in the presence
of 100 μM Lidocaine (green), 100 nM Nifedipine (blue) or 50 nM Dofetilide (red), which show expected effects on
action potential amplitude and duration. B) Average effect of each compound on spontaneous action potential
parameters, presented as percent of control ± SEM, N ≥ 4. Statistical significance calculated by a paired
two-tailed Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001).
Axol’s Human iPSC-Derived Ventricular Cardiomyocytes were treated with doxorubicin (control, 500 nM, 100 nM
and 50 nM). There was a dose-dependent response at 13 h and 24 h post-treatment with doxorubicin.
Arrhythmias and loss of beating amplitude were seen at lower doxorubicin concentration, whereas higher
doxorubicin concentrations resulted in tachycardia and ultimately cell death. Data kindly provided by
Dr J. Maynes, University of Toronto.
Protocols
COPYRIGHT(c) 2008. °í¸¶¹ÙÀÌ¿ÀÅØ(ÁÖ). ALL RIGHTS RESERVED. Contact Webmaster for more information.
°³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ (07207) ¼¿ï½Ã ¿µµîÆ÷±¸ ¾çÆò·Î 21±æ 26 ¼±À¯µµ¿ª1Â÷ ¾ÆÀÌ¿¡½ººñÁö 19Ãþ | TEL 02)579-8787 | FAX 02)578-7042.